Variability of waiting times for the 4 most prevalent cancer types in Ontario: a retrospective population-based analysis

Rastpour, Amir; Begen, Mehmet A.; Louie, Alexander V.; Zaric, Gregory S.

doi:10.9778/cmajo.20170118

Cited by 7 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, after this exclusion we identified 8 manuscripts eligible for the review (2 excluded because not in line with the aim of the study) (Figure 1). 11,12,[17][18][19][20][21][22] The articles were published between 2010 and 2019; the studies have been conducted from 1996 to 2015; they involved a minimum of 16 to a maximum of 95438 participants. Studies have been conducted in Poland, Canada, Sweden, South Africa, United Kingdom (UK) and France.…”

Section: Resultsmentioning

confidence: 99%

“…Two authors reported that high-risk patients had shorter waiting times; one author 17 reported a significantly higher waiting time for patients who underwent radiotherapy, however this time has diminished in the years as reported by Rastpour et al 19 One author observed no differences in survival on the basis of the time of surgery (immediate, or after 4-6 months). 20…”

Section: Other Findingsmentioning

confidence: 92%

See 1 more Smart Citation

Waiting Times for Prostate Cancer: A Review

Lazzeri

Troiano

Porchia

et al. 2020

Journal of Public Health Research

View full text Add to dashboard Cite

Prostate cancer is one of the most common diagnosed cancer in men and the waiting time has become an important issue not only for clinical reasons, but mostly for the psychological implications on patients. The aim of our study was to review and analyze the literature on waiting times for prostate cancer. In February-March 2019 we performed a search for original peer-reviewed papers in the electronic database PubMed (MEDLINE). The key search terms were “prostate cancer AND waiting list”, “prostate cancer AND waiting times”. We included in our narrative review articles in Italian, English or French, published in 2009-2019 containing original data about the waiting times for prostate cancer. The literature search yielded 680 publications. Finally, we identified 8 manuscripts eligible for the review. The articles were published between 2010 and 2019; the studies involved a minimum of 16 to a maximum of 95,438 participants. Studies have been conducted in 6 countries. The waiting times from cancer suspicion to histopathological diagnosis and to treatment had an important reduction in the last years, and this constant decrease could lead to an increase of patients' satisfaction.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Other Findingsmentioning

confidence: 92%

Waiting Times for Prostate Cancer: A Review

Lazzeri

Troiano

Porchia

et al. 2020

Journal of Public Health Research

View full text Add to dashboard Cite

show abstract

“…The total wait time, as well as the interval delays, for lung cancer management in our study were comparable to other published studies. 3,6,8,[14][15][16][17] Two Canadian studies from tertiary hospitals in Hamilton, Ontario, and Montréal, Quebec, evaluated time delays in the care of patients with NSCLC. 8,17 The wait time from symptom onset to treatment in these studies was 138 days in Hamilton and 122 days in Montréal.…”

Section: Discussionmentioning

confidence: 99%

Wait times in the management of non–small cell lung carcinoma before, during and after regionalization of lung cancer care: a high-resolution analysis

Shakeel¹,

Dhanoa²,

Khan³

et al. 2021

cjs

View full text Add to dashboard Cite

Background: Timeliness can have a substantial effect on treatment outcomes, prognosis and quality of life for patients with lung cancer. We sought to evaluate changes in wait times for patients with non–small cell lung carcinoma (NSCLC) and to identify bottlenecks in cancer care. Methods: We included patients who received treatment with curative intent or palliative treatment for NSCLC, diagnosed through mediastinal staging by a thoracic surgeon. Data were collected from 3 cohorts over 3 time periods: before the regionalization of lung cancer care (2005–2007, C1), immediately postregionalization (2011–2013, C2) and 5 years after regionalization (2016–2017, C3). Total wait time and delays along treatment pathways were compared across cohorts using multivariate Cox proportionality models. Results: Our total sample size was 299 patients. Overall, there was no significant difference in total wait time among the 3 cohorts. However, wait time from symptom onset to first physician visit significantly increased in C3 compared with C2 (hazard ratio [HR] 0.41, p < 0.01) and C1 (HR 0.43, p < 0.01). Time from first physician visit to computed tomography (CT) scan significantly decreased in C3 compared with C2 (HR 1.54, p < 0.01). Time from abnormal CT scan to first surgeon visit also significantly decreased in C2 (HR 1.43, p < 0.01) and C3 (HR 4.47, p < 0.01) compared with C1, and between C3 and C2 (HR 2.67, p < 0.01). In contrast, time from first surgeon visit to completion of staging significantly increased in C2 (HR 0.36, p < 0.01) and C3 (HR 0.24, p < 0.01) compared with C1, as well as between C3 and C2 (HR 0.60, p < 0.01). Time to first treatment after completion of staging was significantly shorter for C3 than C1 (HR 1.58, p < 0.01). Conclusion: Trends toward a reduction in wait time are evident 5 years after the regionalization of lung cancer care, primarily led by shorter wait times for CT scans and thoracic surgeon consults. However, wait times can further be reduced by addressing delays in staging completion and patient and provider education to identify the early signs of NSCLC.

show abstract

“…The waiting time for establishing a diagnosis of prostate cancer and instituting treatment varies with country and sometimes between different regions in the same country [ 3 – 6 ]. Generally, there is often public concern about cancers and how quick and easy it is for patients with cancer to assess care [ 7 ]. In addition, a patient's perceived waiting time for cancer treatment has been shown to be important for patient satisfaction [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Waiting Times for Prostate Cancer Diagnosis in a Nigerian Population

Omisanjo

Ogunremi

Akinola

et al. 2021

Journal of Cancer Epidemiology

View full text Add to dashboard Cite

Background. Prostate biopsy remains an important surgical procedure in the diagnostic pathway for prostate cancer, but access to prostate biopsy service is poorly studied in the Nigerian population. While there has been a well-documented delay in patient presentation with prostate cancer in Nigeria, little is however known about how long patients wait to have a histological diagnosis of prostate cancer and start treatment after presenting at Nigerian hospitals. Method. This was a descriptive retrospective study to document the specific duration of the various timelines in getting a diagnosis of prostate cancer at the Lagos State University Teaching Hospital, Ikeja, Nigeria. Results. There were 270 patients. The mean age was 69.50 ± 8.03 years (range 45-90). The mean PSA at presentation was 563.2 ± 1879.2 ng / ml (range 2.05-15400), and the median PSA was 49.3 ng/ml. The median waiting times were (i) 10 days from referral to presentation; (ii) 30 days from presentation to biopsy; (iii) 24 days from biopsy to review of histology; (iv) 1 day from histology review to discussion/planning of treatment. The median overall waiting time from referral to treatment was 103 days. The mean time from presentation to biopsy was significantly shorter for patients with PSA of ≥50 ng/ml compared to those with PSA < 50 ng / ml . p = 0.048 . Overall, the median time from biopsy to histology was significantly shorter for patients whose specimens were processed in private laboratories (17 days) compared to those whose specimens were processed at the teaching hospital laboratory (30 days), p ≤ 0.001 . Conclusion. There is a significant delay within the health care system in getting a prostate cancer diagnosis in the Nigerian population studied. The major points of the identified delay were the waiting time from patient presentation to having a biopsy done and the histology report waiting time.

show abstract

Variability of waiting times for the 4 most prevalent cancer types in Ontario: a retrospective population-based analysis

Cited by 7 publications

References 24 publications

Waiting Times for Prostate Cancer: A Review

Waiting Times for Prostate Cancer: A Review

Wait times in the management of non–small cell lung carcinoma before, during and after regionalization of lung cancer care: a high-resolution analysis

Waiting Times for Prostate Cancer Diagnosis in a Nigerian Population

Contact Info

Product

Resources

About